Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei

por Liedert, Bernd, Pluim, Dick, Schellens, Jan, Thomale, Jürgen
Publicado 2006

Bevacizumab

por Kazazi-Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.
Publicado 2010

Trastuzumab

por Boekhout, Annelies H., Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2011

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

por Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
Publicado 2009

Concise Drug Review: Azacitidine and Decitabine

por Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2013

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

por van Andel, Lotte, Rosing, Hilde, Schellens, Jan HM, Beijnen, Jos H
Publicado en Mar Drugs (2018)

Long-term platinum retention after treatment with cisplatin and oxaliplatin

por Brouwers, Elke EM, Huitema, Alwin DR, Beijnen, Jos H, Schellens, Jan HM
Publicado 2008

Inhibitors of mTOR

por Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
Publicado 2010

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2011

Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects

por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2011

Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics

por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2011

Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism

por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2011

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2013

Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling

por Gast, Marie-Christine W, Engwegen, Judith YMN, Schellens, Jan HM, Beijnen, Jos H
Publicado 2008

Lapatinib for Advanced or Metastatic Breast Cancer

por Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2012

Concise Drug Review: Pazopanib and Axitinib

por van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Publicado 2012

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

por van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
Publicado 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

por Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
Publicado en Clin Pharmacokinet (2017)

Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL

por de Jonge, Milly E, Huitema, Alwin DR, Schellens, Jan HM, Rodenhuis, Sjoerd, Beijnen, Jos H
Publicado 2005

Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications

por Liberti, Lawrence, Stolk, Pieter, McAuslane, James Neil, Schellens, Jan, Breckenridge, Alasdair M., Leufkens, Hubert
Publicado en Oncologist (2015)